PeptImmune, Inc.: Series D $8.2M

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Ventures and Silicon Valley Bank Capital.

MAP Pharmaceuticals, Inc.: Series D $50M

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.

ChemoCentryx, Inc.: Series D $29.9M

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

Orqis Medical Corp.: Series D $37.4M

Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.

TransOral Pharma, Inc.: Series D $40M

TransOral Pharmaceuticals (Point Richmond, CA) a specialty pharmaceutical company CNS platform targeting insomnia and alcohol dependence, closed a $40M Series D financing. The deal was led by New Enterprise Associates additional participants included New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures and Peninsula Equity Partners.

Chimerix, Inc.: Series D $23.1M

Chimerix (Seattle, WA) is applying its technology to the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration, has closed $23.1M in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures.

TechniScan Systems, Inc.: Series D $6.4M

TechniScan Medical Systems (Salt Lake City, UT) developer of ultrasound technology for breast imaging raised $6.4 million in Series D funding from Green and Gold Holdings and private investors.

Locus Pharma, Inc.: Series D $30.2M

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.

Glucon, Inc.: Series D Undisclosed

Glucon (Boulder, CO) developer of a blood glucose measurement system raised an undisclosed amount of Series D funding. The deal was led by the 3i Group and was joined by Sequel Venture Partners, Quest Capital Partnership, Hunt Ventures and previous investors Aurum Ventures, Giza Venture Capital, MKI, Infinity Venture Capital Fund and Ascend Technology Ventures.

Blue Heron Biotechnology, Inc.: Series D $3.7M

Blue Heron Biotechnology (Bothell, WA) a provider of gene synthesis services raised approximately $3.7M in Series D funding. Participants include Crabtree Ventures, Integra Ventures and Invitrogen.